515
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Cancer Epidemiology

Changes in incidence trends of meningioma in Finland, 1990–2017: analysis of Finnish Cancer Registry data

, &
Pages 994-1000 | Received 15 Feb 2023, Accepted 14 Jul 2023, Published online: 05 Sep 2023
 

Abstract

Background

Meningiomas are the most common primary neoplasm of the central nervous system. Previous research on the incidence of meningioma in Finland showed an increase in the age-standardized incidence rate over three decades (1968–1997). In this study, we analysed meningioma incidence in Finland during 1990–2017.

Materials and methods

Data on 9842 meningioma patients were obtained from the Finnish Cancer Registry, and population size by calendar year, sex, and age group from Statistics Finland. The European Standard Population was used to calculate age-standardized incidence rates. Poisson regression was used to evaluate differences by sex and age, and joinpoint regression to examine changes in trend.

Results

At the beginning of the study period, the age-standardized incidence of meningioma for men was 2.35/100,000 and for women 6.96/100,000. In the end, it was 4.09/100,000 and 10.19/100,000, respectively. The annual percent change (APC) for women was +4.6 (95% confidence interval, CI 3.10 to 6.20) from 1990 to 2001 and −1.0 (95% CI −1.70 to −0.30) from 2001 to 2017. For men, the APC was +3.1 (95% CI 0.80–5.40) during 1990–2002 and −0.9 (95% CI −2.10 to 0.30) in 2002–2017. The incidence of meningioma in women was 2.8 times higher than in men (rate ratio 2.81; 95% CI 2.68–2.94).

Conclusions

Meningioma incidence increased in both sexes from 1990, but the trend reversed in 2001–2002. Medical imaging or risk factors do not appear to explain the changes.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data (meningioma cases and incidence) are available from registry authorities, as according to Finnish regulations, researchers are not allowed to forward confidential non-anonymous health data to any third parties.

Additional information

Funding

This work was supported by the Competitive State Research Financing administered by Tampere University Hospital under Grant number VTR/MK278.